GET DAILY SIGNALSOscar Health (OSCR): Analyst Targets Suggest Room for a +15% Advance to $37
Key Takeaways
- The central target used here is $37, the arithmetic mean of nine verified analyst price targets for Oscar Health, Inc. (OSCR).
- At the latest verified price of roughly $32.14, reaching $37 would require an advance of about 15%.
- Individual analyst price targets span a wide range, from a low of $27 to a high of $49, reflecting sharply divided views on valuation and growth durability.
- The strongest supporting factors are record profitability, materially raised 2026 operating-earnings guidance, and expansion of its Affordable Care Act (ACA) footprint.
- The biggest risks are a demanding valuation after a powerful rally, ACA subsidy and policy uncertainty, and notable insider selling by executives.
- Several analysts keep cautious ratings even as the stock has surged, suggesting much of the near-term upside is already reflected in consensus estimates.
Understanding the Analyst Consensus
Oscar Health is a New York-based, technology-driven health insurer offering individual and family (primarily ACA marketplace), small-group, and Medicare Advantage plans, alongside its licensed "+Oscar" technology platform. The company is led by CEO Mark Bertolini, formerly of Aetna.
The $37 central target is calculated from nine current, individually verified analyst price targets rather than copied from any single headline consensus. The targets reviewed include Barclays ($49), Piper Sandler ($45), Raymond James ($42), UBS ($38), Stephens & Co. ($34), Baird ($33), Jefferies ($31), Bank of America Securities ($30), and Wells Fargo ($27), spanning roughly August through November 2026. Their arithmetic mean is approximately $36.60, which rounds to a clean $37.
The dispersion is striking. Barclays, Piper Sandler, and Raymond James carry bullish stances well above the mean, while Bank of America Securities remains Underperform and Wells Fargo sits at the low end. Most firms have neutral ratings, a sign that analysts see the growth story as real but largely priced in. Notably, several firms — Barclays, UBS, and Jefferies — upgraded OSCR from bearish stances during 2026, and targets have generally been revised upward as results improved. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Valuation and the Road to the Target
With shares near $32.14, moving to $37 requires about a 15% gain — a substantial but not extraordinary move for a stock that has already climbed more than 120% year to date and trades well above its 52-week low of $10.69. The 52-week high sits near $38.50, meaning the central target sits just below the stock's own recent peak.
The path would likely depend on continued execution: sustained premium revenue growth, stable or improving medical cost ratios, and delivery on the raised full-year 2026 operating-earnings guidance of $850 million to $950 million. Revenue is projected to reach roughly $18.99 billion in 2026, up more than 60% from 2025, with EPS (earnings per share) forecast around $2.17 versus a loss the prior year. A forward P/E (price-to-earnings ratio) near 15 leaves some room for multiple expansion if earnings keep compounding, but also limits downside cushion if growth decelerates.
Factors That Could Support Further Gains
The most compelling support is the company's dramatic swing to profitability. Third-quarter 2026 revenue rose more than 70% year over year, and management lifted full-year operating-earnings guidance — evidence that scale is translating into operating leverage. Expansion to roughly 713 counties across 21 states broadens the growth runway, while the +Oscar licensing business offers a non-premium revenue stream. A steady cadence of analyst upgrades through 2026 — Barclays to Overweight and UBS from Sell to Neutral among them — reflects improving fundamental sentiment.
Key Risks to Consider
The principal obstacle is valuation and positioning. After a triple-digit run, the stock trades near or above several analysts' targets, and the wide $27-to-$49 range signals genuine disagreement about how much of the turnaround is already discounted. Oscar's heavy concentration in ACA individual plans leaves it exposed to federal subsidy and regulatory changes, a recurring risk for marketplace insurers. Medical cost trends could also pressure margins if claims accelerate. Insider activity adds a cautionary note: the CEO and other officers and directors have sold significant share volumes through 2026, which some investors read as a signal of limited near-term upside.
Technical Picture and Levels to Watch
The stock reversed sharply after briefly touching $37.50–$37.95 in pre-market trading following its early-November earnings report, closing lower despite the beat. The $38.50 52-week high is the key overhead resistance zone, with the $40 level serving as the next psychological barrier. On the downside, the $30–$31 area, near recent consolidation, is a meaningful support level to watch, though it is far above the 52-week low. The share price has slipped back below shorter-term moving averages, indicating the rally is consolidating rather than extending in a straight line.
Time Horizon and Items to Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms rarely publish identical timeframes. Investors focused on the $37 target should watch quarterly medical cost ratios and membership growth, the next earnings report and any guidance updates, further analyst revisions (particularly from the bearish camp), and federal developments affecting ACA subsidies. Elevated insider selling and the stock's reaction around the $38.50 prior high are also worth monitoring for signs of whether the rally can resume.
Exploring AI Daily Buy/Sell Signals
In my analysis of names like OSCR, I find it helpful to layer in systematic tools. Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and AI-driven analysis. This offers a structured way to track momentum shifts alongside fundamental research.
Overall Assessment
The $37 target — the mean of nine verified analyst price targets — represents about 15% upside from the latest price, a level just below the stock's own 52-week high. Reaching it would require Oscar Health to keep converting rapid revenue growth into expanding margins while sidestepping ACA policy risk and valuation fatigue. The bullish case rests on raised guidance and a string of upgrades; the cautious case points to a stock trading near or above several targets, heavy insider selling, and a wide, divided analyst range. With targets clustered from $27 to $49, the balance of evidence suggests the target is reachable but far from assured, and investors should treat the figure as an analytical benchmark rather than a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OSCR in upward trend: price rose above 50-day moving average on November 09, 2026
OSCR moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on OSCR as a result. In 62 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +13.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where OSCR advanced for three days, in 232 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 174 of 225 cases where OSCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for OSCR turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The 10-day moving average for OSCR crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OSCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
OSCR broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating fairly steady price growth. OSCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.610) is normal, around the industry mean (3.520). P/E Ratio (19.277) is within average values for comparable stocks, (126.353). OSCR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.618) is also within normal values, averaging (0.569).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare
Advertisement